Unilife Signs 10-yr Supply Agreement With Global Pharma Company - Quick Facts

(RTTNews) - Unilife Corp. (UNIS) announced the signing of a worldwide 10 year Commercial Supply Agreement with a global pharmaceutical company for the use of the Depot-ject delivery system with an approved ocular injection therapy. The company said the identity of the pharmaceutical company and its target therapy, which is approved in the U.S and Europe for the treatment of a high prevalence disease of the retina, will remain confidential.

Unilife anticipates the commercial availability of Depot-ject with the therapy after a 12 to 24 month process of customization and regulatory approval for the drug-device combination.